The evidence from the REACH-2/REACH trials and ensuing pooled data analysis demonstrated, for the first time, that baseline AFP levels are also an important predictive biomarker to select those patients with HCC who are set to benefit most from ramucirumab treatment. The gene discussed is AFP; the disease is hepatocellular carcinoma.